Physician profile
Christopher Opella
NPI 1134184716
$1,016.16
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $197 · 2021: $525 · 2022: $67.99 · 2024: $20.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $20.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.81 | 2019-2021 | |
| Esperion Therapeutics, INC. | $222.69 | 2020-2022 | |
| Lilly USA, LLC | $81.56 | 2019-2021 | |
| Genentech USA, INC. | $80.28 | 2019-2022 | |
| Novo Nordisk INC | $69.11 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $66.00 | 2020-2024 | Airsupra |
| Abbvie INC. | $56.56 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $53.77 | 2020-2021 | |
| Currax Pharmaceuticals LLC | $24.80 | 2021 | |
| Amarin Pharma, INC. | $23.34 | 2020 | |
| Sanofi-Aventis U.S. LLC | $22.48 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.95 | 2020 | |
| Janssen Pharmaceuticals, INC | $16.69 | 2021 | |
| Nabriva Therapeutics, Plc | $15.56 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.80 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.38 | 2019 | |
| Merck Sharp & Dohme LLC | $13.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Opella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.